Imatinib Mesylate Tablet, Film Coated
Product Images NDC 82249-020

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Imatinib Mesylate (NDC 82249-020). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Civica Script Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Imatinibcontainerlabel100mg90stablets (Imatinibcontainerlabel100mg90stablets)

This text contains information about a prescription medication with the NDC code 82249-020-90, which is a film-coated tablet containing 119.50 mg of imatinib mesylate equivalent to 100 mg of imatinib free base. The recommended storage temperature is between 20°C to 25°C (68°F to 77°F) in a controlled room temperature, protected from moisture. The medication is dispensed in a tight container and should be kept out of reach of children. Additional details such as dosage instructions, manufacturer, and distributor information are also provided.*

FDA Label Image

Imatinibcontainerlabel400mg30stablets (Imatinibcontainerlabel400mg30stablets)

Each film-coated tablet of Imatinib Mesylate contains 478 mg of imatinib mesylate equivalent to 400 mg of imatinib free base. The recommended dosage can be found in the prescribing information. Store between 20°C to 25°C (68°F to 77°F) with excursions permitted to 15°C to 30°C (59°F to 86°F). It is important to protect the tablets from moisture by keeping them in a tight container. Distributor: CivicaScript, LLC, Lehi, UT 84048. Manufacturer: Hetero Labs Limited, India. For more details, visit the website given or scan the provided QR code.*

FDA Label Image

Imatinibfigure1 (Imatinibfigure1)

FDA Label Image

Imatinibfigure2 (Imatinibfigure2)

This text provides data on the outcomes of patients receiving Imatinib Mesylate with progression to AP or BC. It includes the number of patients, censoring information, hazard ratio, and log-rank test results. The results suggest a significant impact of Imatinib Mesylate on the progression of the disease.*

FDA Label Image

Imatinibfigure3 (Imatinibfigure3)

FDA Label Image

Imatinibfigure4 (Imatinibfigure4)

FDA Label Image

Imatinibfigure5 (Imatinibfigure5)

This text provides information about the probability of overall survival and hazard ratio. The probability is given as P=0.0187 and the hazard ratio is 0.45. The data appears to include survival times in months, censored observations, and at-risk events. The information seems to be related to a study or analysis of survival rates over a period of time.*

FDA Label Image

Imatinibstructure (Imatinibstructure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.